We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
237 hedge funds and large institutions have $1.71B invested in Iovance Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 101 increasing their positions, 71 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
77% more call options, than puts
Call options by funds: $32.1M | Put options by funds: $18.1M
42% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 71
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
2.18% more ownership
Funds ownership: 99.21% → 101.39% (+2.2%)
5% less funds holding
Funds holding: 249 → 237 (-12)
18% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 50
34% less capital invested
Capital invested by funds: $2.6B → $1.71B (-$888M)
Holders
237
Holders Change
-12
Holders Change %
-4.82%
% of All Funds
3.99%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
41
Increased
101
Reduced
71
Closed
50
Calls
$32.1M
Puts
$18.1M
Net Calls
+$14M
Net Calls Change
-$20.3M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$64.5M |
| 2 |
BlackRock
New York
|
+$54.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.3M |
| 4 |
D.E. Shaw & Co
New York
|
+$25.6M |
| 5 |
Goldman Sachs
New York
|
+$18.1M |
